8-K: Viemed Healthcare Reports Strong Q1 2025 Results, Updates Full-Year Guidance and Announces Acquisition

Viemed Healthcare announces a 17% increase in Q1 2025 revenue, driven by growth in ventilator and PAP therapy patient counts, and updates its full-year guidance while also announcing an agreement to acquire Lehans Medical Equipment.

Summary

• Viemed Healthcare reported its financial results for the three months ended March 31, 2025.
• Net revenues for Q1 2025 were $59.1 million, a 17% increase compared to Q1 2024.
• Net income attributable to Viemed for Q1 2025 was $2.6 million, or $0.06 per diluted share, a 64% increase year-over-year.
• Adjusted EBITDA for Q1 2025 totaled $12.8 million, a 26% increase compared to Q1 2024.
• The company's ventilator patient count increased to 11,809 as of March 31, 2025, a 13% increase year-over-year.
• PAP therapy patient count increased to 22,899 as of March 31, 2025, a 46% increase year-over-year.
• Sleep resupply patient count was 22,941 as of March 31, 2025, a 21% increase year-over-year.
• The company maintains a strong cash balance of $10.2 million and working capital of $13.6 million as of March 31, 2025.
• Long-term debt as of March 31, 2025, amounted to $3.5 million, and the company has $55 million available under existing credit facilities.
• Net revenue for the year ending December 31, 2025, is expected to be in the range of $256 million to $265 million, increased from the prior range of $254 million to $265 million.
• Adjusted EBITDA for the year ending December 31, 2025, is expected to be in the range of $55 million to $58 million, increased from the prior range of $54 million to $58 million.
• Viemed agreed to acquire Lehans Medical Equipment for approximately $26 million, subject to adjustments and contingent payments, expected to close in Q3 2025.
• Lehan generated net revenues of approximately $25.7 million and Adjusted EBITDA of approximately $7.4 million in 2024.
• Viemed has not included the anticipated impact of this acquisition in its full year 2025 guidance but intends to update its outlook upon closing.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong Q1 results, increased guidance, and a strategic acquisition. The management's comments are optimistic, and the company's financial position appears solid.

Positives

• Viemed's net revenues increased by 17% year-over-year.
• Net income attributable to Viemed increased by 64% year-over-year.
• Adjusted EBITDA increased by 26% year-over-year.
• Ventilator patient count grew by 13% year-over-year.
• PAP therapy patient count increased significantly by 46% year-over-year.
• The company updated its full-year 2025 revenue and Adjusted EBITDA guidance upwards.
• Viemed is acquiring Lehans Medical Equipment, which generated $25.7 million in revenue and $7.4 million in Adjusted EBITDA in 2024.
• The company has a strong cash balance and available credit facilities.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties, including general business, market, and economic conditions.
• Reductions in reimbursement rates and audits of reimbursement claims by governmental and private payor entities could negatively impact the company.
• The company faces competition and depends on key suppliers.
• Disruptions in or attacks on the company's information technology systems could negatively impact operations.
• Difficulty integrating newly acquired businesses could impact performance.
• The company is subject to a difficult litigation and regulatory environment.
• The occurrence of natural and unnatural catastrophic events or health epidemics or concerns could negatively impact the company.

Future Outlook

Viemed expects net revenue for the year ending December 31, 2025, to be in the range of $256 million to $265 million and Adjusted EBITDA to be in the range of $55 million to $58 million. The company anticipates continued growth in complex respiratory, sleep, and staffing businesses. The acquisition of Lehans Medical Equipment is expected to close in Q3 2025, and the company intends to update its full-year outlook to incorporate the anticipated contributions from the acquisition.

Management Comments

• Casey Hoyt, Viemed's CEO, noted that they are pleased to see marked improvement in each of their businesses in what has historically been their toughest quarter.
• The strong start to the year has given them the confidence to tighten their guidance by raising the lower end of their revenue and Adjusted EBITDA ranges.
• This performance is directly attributable to returns they are already seeing from the structure they put in place in 2024 to improve their sales organization and accelerate the hiring of new reps, as well as the leveraging of investments in technology for greater efficiencies.
• The strong balance sheet continues to facilitate the opportunity they have pursued for the past 12 months to significantly improve and extend the life of their ventilator fleet.
• The strong capital position and cash flow are also enabling them to layer on inorganic growth such as the acquisition of Lehan's Medical Equipment later this year that is expected to complement the growth they are experiencing in the complex respiratory, sleep and staffing businesses.
• Viemed believes they are perfectly positioned to help improve lives through compassionate care in the home.

Industry Context

Viemed's focus on in-home clinical care and technology-enabled services aligns with the broader industry trend of shifting healthcare towards more efficient and patient-centric models. The acquisition of Lehans Medical Equipment suggests a strategy to expand its market presence and service offerings in the respiratory care and women's health sectors. The company's emphasis on reducing hospital readmissions and lowering the total cost of care positions it favorably in a healthcare landscape increasingly focused on value-based care.

Comparison to Industry Standards

• Without specific competitor data for 2025, we can only infer based on historical trends.
• Companies like AdaptHealth and Rotech Healthcare also operate in the home medical equipment and respiratory care space.
• Viemed's 17% revenue growth and 26% Adjusted EBITDA growth in Q1 2025 suggest a strong performance compared to industry averages, assuming similar growth rates aren't universally experienced.
• The acquisition of Lehans Medical Equipment for approximately $26 million, with Lehan's generating $25.7 million in revenue and $7.4 million in Adjusted EBITDA in 2024, appears to be a strategic move to enhance market share and service offerings, similar to other consolidation activities seen in the industry.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance and increased guidance.
• Employees: Potential for growth and development due to company expansion and acquisition.
• Patients: Continued access to respiratory care and technology-enabled home medical equipment services.
• Hospitals and Health Systems: Potential for fewer readmissions through Viemed's services.
• Payers: Potential for lower total cost of care versus institutional settings.

Next Steps

• The company will host a conference call on May 8, 2025, to discuss the results.
• The company expects to close the acquisition of Lehans Medical Equipment in the third quarter of 2025.
• Viemed intends to update its full-year outlook to incorporate the anticipated contributions from the Lehans acquisition upon closing.
• The company expects to conclude the ventilator buybacks in June with remaining payments from the vendor occurring in early Q3.

Key Dates

Keywords

Viemed Healthcare, Financial Results, Q1 2025, Guidance, Acquisition, Respiratory Care, Home Medical Equipment, Ventilator, PAP Therapy, EBITDA, Revenue